search
Back to results

Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function

Primary Purpose

Cerebrovascular Disorders, Cerebrovascular Disease

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Flow mediated dilation (brachial and femoral arteries)
Cerebral vascular reactivity to carbon dioxide (CO2)
Cerebral vascular function test
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cerebrovascular Disorders focused on measuring brain blood flow, brain vascular function

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Young and Older Healthy Adults:

  • Males and females willing and able to provide informed consent
  • Aged between 18-35 years (Young) or 60-80 years (Older)
  • Premenopausal women will be tested within 1-4 days after menses begins to control for hormone status
  • Women taking oral contraceptives will be allowed to participate and they will be tested in the low hormone or placebo phase
  • Postmenopausal women (at least 12 months since last menstrual cycle) who are not on hormone replacement therapy will be eligible
  • Sedentary or recreationally active
  • Non-tobacco/nicotine users (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
  • Laboratory measured systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg
  • Normal 12-lead ECG (reviewed by a physician)
  • Normal clinical results from a medical exam reviewed by a board certified physician (e.g., Medical & Behavioral Health Questionnaire - see attached document)
  • Body mass index (BMI) <40 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2); this criteria is used to ensure subjects will fit inside the LBNP chamber
  • Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions

Young and Older Chronic Smokers of Tobacco Cigarettes:

The same criteria (a-c and e-i above) as Young and Older Healthy Adults, except:

- Chronic smokers of tobacco cigarettes only (i.e., at least 20 pack year use)

Exclusion Criteria:

Young and Older Healthy Adults:

  • Age <18 years, or 40-60 years, or >80 years
  • Body mass index (BMI) >40 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
  • Regular tobacco/nicotine users within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
  • Not abstaining from the following 24 hours prior to the familiarization session and the experimental session: exercise, alcoholic substances, prescription or non-prescription medications (unless cleared by the medical screener), dietary supplements, herbal medications, caffeinated substances (including coffee, tea (iced or hot), caffeinated energy drinks or sodas).
  • Not fasted for at least 3-4 hours prior to the experimental sessions.
  • Positive pregnancy test
  • Hormone replacement therapy (males and females)
  • Females with an erratic/irregular menstrual cycle
  • Females who are using a continually-releasing hormonal (e.g., NuvaRing™ or other hormone-releasing vaginal rings, Depo Provera shot, birth control implants such as Nexplanon) and who do not have a regular menstrual cycle
  • Use of prescription drugs, non-prescription drugs or herbal medicines known to alter autonomic function unless cleared prior to the study
  • Any metabolic disease, except individuals who are on cholesterol-lowering medications (older subjects only; young subjects on cholesterol-lowering medications will be excluded)
  • Use of two or more anti-hypertensive medications (older subjects only; young subjects on anti-hypertensive medications will be excluded)
  • Use of beta blockers
  • Frequent use of bronchodilators
  • Use of anti-coagulant therapy
  • Current or past history of hyperthyroidism, or other thyroid hormone-related disease
  • Signs of cardiovascular abnormalities (e.g., resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg; abnormal 12-lead ECG)
  • History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy)
  • Known history of atherosclerosis of the carotid arteries (i.e., plaque formation)
  • Known history of peripheral artery disease (PAD)
  • Concussion and or other loss of consciousness within the past 30 days.
  • Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder)
  • Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease)
  • History of anaphylaxis
  • History of pre-syncopal/syncopal episodes or orthostatic hypotension
  • Donated blood within the last 60 days
  • History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs
  • Known or suspected abdominal hernia
  • History of alcohol or drug abuse which inhibits the subject's ability to complete this study
  • Known depression, anxiety, or any other mental health issue which inhibits the subject's ability to complete this study

Young and Older Chronic Smokers of Tobacco Cigarettes

The same criteria (a-b and d-dd above) as Young and Older Healthy Adults, except:

- Less than 20 pack year use of tobacco cigarettes, or regular use of other tobacco/nicotine products within the last 6 months (e.g., electronic cigarettes, chewing tobacco, nicotine gum or patches).

Sites / Locations

  • University of Illinois at ChicagoRecruiting
  • University of North Texas Health Science CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Arm 1

Arm Description

Outcomes

Primary Outcome Measures

Cerebral vascular function
Assessment of internal carotid artery dilation and blood flow in response to a reactive hyperemic stimulus
Cerebral vascular reactivity to carbon dioxide (CO2)
Assessment of blood flow (or velocity) through the internal carotid artery and middle cerebral artery with a standardized CO2 stimulus (+5 mmHg)
Flow mediated dilation (brachial and femoral arteries)
Assessment of artery dilation and blood flow in response to a reactive hyperemic stimulus

Secondary Outcome Measures

Full Information

First Posted
April 1, 2020
Last Updated
May 17, 2022
Sponsor
University of Illinois at Chicago
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT04336852
Brief Title
Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function
Official Title
Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 14, 2018 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this study is to develop a test of cerebral vessel function by inducing a reactive hyperemia that will elicit a rapid and profound increase in cerebral vessel shear stress. The results of this project may lead to development of a test with prognostic/predictive utility for individual risk assessment of a future cerebrovascular event/disease. This information will be of vital importance to the medical community in regards to cerebrovascular health in aging individuals, and testing of interventions and therapies that may ameliorate these effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebrovascular Disorders, Cerebrovascular Disease
Keywords
brain blood flow, brain vascular function

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Three groups of subjects (young, older, cigarette smokers) complete the same intervention, in an independent-group design.
Masking
None (Open Label)
Allocation
N/A
Enrollment
93 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Flow mediated dilation (brachial and femoral arteries)
Intervention Description
Assessment of vascular function of the brachial and femoral arteries.
Intervention Type
Procedure
Intervention Name(s)
Cerebral vascular reactivity to carbon dioxide (CO2)
Intervention Description
Cerebral blood flow responses to increasing partial pressure of CO2
Intervention Type
Procedure
Intervention Name(s)
Cerebral vascular function test
Intervention Description
Cerebral blood flow responses to a reactive hyperemia stimulus
Primary Outcome Measure Information:
Title
Cerebral vascular function
Description
Assessment of internal carotid artery dilation and blood flow in response to a reactive hyperemic stimulus
Time Frame
3-months
Title
Cerebral vascular reactivity to carbon dioxide (CO2)
Description
Assessment of blood flow (or velocity) through the internal carotid artery and middle cerebral artery with a standardized CO2 stimulus (+5 mmHg)
Time Frame
3-months
Title
Flow mediated dilation (brachial and femoral arteries)
Description
Assessment of artery dilation and blood flow in response to a reactive hyperemic stimulus
Time Frame
3-months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Young and Older Healthy Adults: Males and females willing and able to provide informed consent Aged between 18-35 years (Young) or 60-80 years (Older) Premenopausal women will be tested within 1-4 days after menses begins to control for hormone status Women taking oral contraceptives will be allowed to participate and they will be tested in the low hormone or placebo phase Postmenopausal women (at least 12 months since last menstrual cycle) who are not on hormone replacement therapy will be eligible Sedentary or recreationally active Non-tobacco/nicotine users (e.g., cigarettes, chewing tobacco, nicotine gum or patches) Laboratory measured systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg Normal 12-lead ECG (reviewed by a physician) Normal clinical results from a medical exam reviewed by a board certified physician (e.g., Medical & Behavioral Health Questionnaire - see attached document) Body mass index (BMI) <40 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2); this criteria is used to ensure subjects will fit inside the LBNP chamber Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions Young and Older Chronic Smokers of Tobacco Cigarettes: The same criteria (a-c and e-i above) as Young and Older Healthy Adults, except: - Chronic smokers of tobacco cigarettes only (i.e., at least 20 pack year use) Exclusion Criteria: Young and Older Healthy Adults: Age <18 years, or 40-60 years, or >80 years Body mass index (BMI) >40 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2) Regular tobacco/nicotine users within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches) Not abstaining from the following 24 hours prior to the familiarization session and the experimental session: exercise, alcoholic substances, prescription or non-prescription medications (unless cleared by the medical screener), dietary supplements, herbal medications, caffeinated substances (including coffee, tea (iced or hot), caffeinated energy drinks or sodas). Not fasted for at least 3-4 hours prior to the experimental sessions. Positive pregnancy test Hormone replacement therapy (males and females) Females with an erratic/irregular menstrual cycle Females who are using a continually-releasing hormonal (e.g., NuvaRing™ or other hormone-releasing vaginal rings, Depo Provera shot, birth control implants such as Nexplanon) and who do not have a regular menstrual cycle Use of prescription drugs, non-prescription drugs or herbal medicines known to alter autonomic function unless cleared prior to the study Any metabolic disease, except individuals who are on cholesterol-lowering medications (older subjects only; young subjects on cholesterol-lowering medications will be excluded) Use of two or more anti-hypertensive medications (older subjects only; young subjects on anti-hypertensive medications will be excluded) Use of beta blockers Frequent use of bronchodilators Use of anti-coagulant therapy Current or past history of hyperthyroidism, or other thyroid hormone-related disease Signs of cardiovascular abnormalities (e.g., resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg; abnormal 12-lead ECG) History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy) Known history of atherosclerosis of the carotid arteries (i.e., plaque formation) Known history of peripheral artery disease (PAD) Concussion and or other loss of consciousness within the past 30 days. Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder) Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease) History of anaphylaxis History of pre-syncopal/syncopal episodes or orthostatic hypotension Donated blood within the last 60 days History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs Known or suspected abdominal hernia History of alcohol or drug abuse which inhibits the subject's ability to complete this study Known depression, anxiety, or any other mental health issue which inhibits the subject's ability to complete this study Young and Older Chronic Smokers of Tobacco Cigarettes The same criteria (a-b and d-dd above) as Young and Older Healthy Adults, except: - Less than 20 pack year use of tobacco cigarettes, or regular use of other tobacco/nicotine products within the last 6 months (e.g., electronic cigarettes, chewing tobacco, nicotine gum or patches).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexander J Rosenberg, PhD
Phone
312-996-9607
Email
arosen26@uic.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Bo Fernhall, PhD
Phone
312-996-6695
Email
fernhall@uic.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander J Rosenberg, PhD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Illinois at Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander J Rosenberg, PhD
Phone
312-996-9607
Email
arosen26@uic.edu
First Name & Middle Initial & Last Name & Degree
Bo Fernhall, PhD
Phone
312-996-6695
Email
fernhall@uic.edu
First Name & Middle Initial & Last Name & Degree
Tracy Baynard, PhD
Facility Name
University of North Texas Health Science Center
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Rickards, PhD
Phone
817-735-2735
Email
caroline.rickards@unthsc.edu
First Name & Middle Initial & Last Name & Degree
Caroline Rickards

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function

We'll reach out to this number within 24 hrs